Sign In
Buy ALXO
$1.67
-0.110 (-6.18%)
At Close: Jun 03, 2026
The 3 Best Biotech Stocks to Buy Right Now
06:55am, Friday, 27'th Aug 2021
Let your portfolio reflect your personality.
So What's Going On With ALX Oncology's Stock?
12:19pm, Monday, 23'rd Aug 2021
ALX Oncology Holdings Inc (NASDAQ: ALXO) shares are trading higher by 19.3% at $74.69, potentially in sympathy with Trillium Therapeutics which announced an acquisition by Pfizer Monday. ALX Oncology
ALX Oncology Shares Increase Over 25% Pre-Market: Why It Happened
08:19am, Monday, 23'rd Aug 2021
The shares of ALX Oncology Holdings Inc (NASDAQ: ALXO) increased by over 25% pre-market. This is why it happened.
ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
04:05pm, Thursday, 12'th Aug 2021
BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47
This Biotech Stock Is Too Cheap to Ignore
09:40am, Thursday, 29'th Jul 2021
Wall Street's short attention span has created an attractive entry point in this once-loved biotech.
The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initia
ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy?
07:45am, Monday, 12'th Jul 2021
ALX Oncology (ALXO) has been struggling lately, but the selling pressure may be coming to an end soon.
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
10:16am, Tuesday, 06'th Jul 2021
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the bi
ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer
09:15am, Tuesday, 06'th Jul 2021
ALX Oncology Holdings Inc (NASDAQ: ALXO) announced updated data from its ongoing ASPEN-01 Phase 1b trial evaluating ALX148 in combination with trastuzumab and chemotherapy to treat gastric or gastr
-- ORR of 72% Observed in Patients with > 2L HER2 Positive Gastric or Gastroesophageal Junction Cancer -- Estimated OS at 12 months of 76% -- ALX Oncology to Host Conference Call on July 6 th at 8
ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies
07:00am, Monday, 14'th Jun 2021
--Interim report completed by ALX for a standard ongoing non-clinical safety study
Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASPEN-01 Phase 1b Trial in Gastric Cancer Patients Randomized Phase 2/3 Study is Planned Based on Promising Results from the A
- The first of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer
04:05pm, Wednesday, 21'st Apr 2021
Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction canc
ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148
07:00am, Monday, 05'th Apr 2021
BURLINGAME, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD4
